{"id":391716,"date":"2014-03-17T00:00:00","date_gmt":"2014-03-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/latron0214-biopharma-malignant-melanoma-tafinlar-and-mekinist-wave-2-launchtrends-us-2014\/"},"modified":"2026-03-31T09:05:41","modified_gmt":"2026-03-31T09:05:41","slug":"latron0214-biopharma-malignant-melanoma-tafinlar-and-mekinist-wave-2-launchtrends-us-2014","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/latron0214-biopharma-malignant-melanoma-tafinlar-and-mekinist-wave-2-launchtrends-us-2014\/","title":{"rendered":"Malignant Melanoma [Tafinlar and Mekinist (Wave 2)] | LaunchTrends | US | 2014"},"content":{"rendered":"<p>LaunchTrends: Tafinlar and Mekinist is a series of three post-launch syndicated reports designed to track physician perception and uptake of newly launched Tafinlar (GlaxoSmithKline\u2019s dabrafenib) and Mekinist (GlaxoSmithKline\u2019s trametinib).<br \/>\nLaunchTrends: Tafinlar and Mekinist measures the impact of these new agents on the unresectable and metastatic melanoma market following launch. The study surveys medical oncologists from the United States and conducts qualitative interviews with physicians. This report evaluates physicians\u2019 current awareness and perception of Tafinlar and Mekinist and Tafinlar and Mekinist combination therapy relative to other currently available therapies for unresectable and metastatic melanoma, current and anticipated usage of Tafinlar, Mekinist, and Tafinlar\/Mekinist combination therapy, and promotional activity of Tafinlar and Mekinist.<\/p>\n","protected":false},"template":"","class_list":["post-391716","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-malignant-melanoma","biopharma-geography-us","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391716","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391716\/revisions"}],"predecessor-version":[{"id":394839,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391716\/revisions\/394839"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391716"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}